SCF Multi-Neurosystems Shock State (MNSS) Atlas | Temporal Windows of Toxic Encephalopathy

SCF-ECCA-TOX-TEMP-0003

Temporal Windows of Toxic Encephalopathy

SCF Multi-Neurosystems Shock State (MNSS) Atlas

Pre-Toxic → Toxic Encephalopathy → Post-Toxic Recovery Mapping

Integrated Neuroimmune, Neurocardiac, Neurovascular, Neurometabolic, Neuroendocrine, Neuroglial, Neuroaxonal, and Connectomic Biomarker Framework

I. SCF TEMPORAL ARCHITECTURE OF TOXIC ENCEPHALOPATHY

Toxic encephalopathy rarely begins at symptom onset.

The SCF model identifies:

Phase A

Pre-Toxic Compensation

↓

Phase B

Silent Toxic Priming

↓

Phase C

Pre-Encephalopathic Shock

↓

Phase D

Early Toxic Encephalopathy

↓

Phase E

Established Toxic Encephalopathy

↓

Phase F

Acute Multi-Neurosystems Shock

↓

Phase G

Recovery Initiation

↓

Phase H

Connectomic Reconstruction

↓

Phase I

Post-Encephalopathy Adaptive State

II. PHASE A — PRE-TOXIC COMPENSATED STATE

SCF Classification

MNSS-0

Temporal Window

Months to Years Before Exposure

Biological State

Normal homeostasis

Neuroimmune Biomarkers

Biomarker	Baseline
IL-6	<2 pg/mL
TNF-α	<5 pg/mL
IL-1β	<1 pg/mL
HMGB1	Low

Neurocardiac Biomarkers

Biomarker	Baseline
HRV SDNN	>100 ms
RMSSD	>30 ms
Troponin	Normal
NT-proBNP	Normal

Neurovascular Biomarkers

Biomarker	Baseline
S100B	<0.1 ng/mL
MMP-9	<150 ng/mL
VEGF	Physiologic

Neurometabolic Biomarkers

Biomarker	Baseline
Lactate	<2 mmol/L
ATP Production	Normal
CoQ10	Normal
cf-mtDNA	Low

Neuroendocrine Biomarkers

Biomarker	Baseline
Cortisol	Circadian normal
ACTH	Normal
DHEA-S	Normal
Melatonin	Normal

Reversibility

Maximum

III. PHASE B — SILENT TOXIC PRIMING

SCF Classification

MNSS-IA

Temporal Window

Minutes to Days Following Exposure

Dominant Shock State

Subclinical Neuroimmune Shock

Neuroimmune Changes

Biomarker	Change
IL-6	↑10–50%
TNF-α	↑
HMGB1	↑
MCP-1	↑

Neurocardiac Changes

Biomarker	Change
SDNN	↓10%
RMSSD	↓
LF/HF	↑

Neurovascular Changes

Biomarker	Change
MMP-9	↑
VEGF	↑

Neurometabolic Changes

Biomarker	Change
Lactate/Pyruvate Ratio	↑
ATP Production	↓10%

Neuroendocrine Changes

Biomarker	Change
Cortisol	↑
ACTH	↑

Clinical Findings

Usually asymptomatic

Therapeutic Opportunity

Highest-value intervention window

IV. PHASE C — PRE-ENCEPHALOPATHIC SHOCK

SCF Classification

MNSS-IB

Temporal Window

Hours to Days Before Symptoms

Dominant Shock State

Multi-System Toxic Priming

Neuroimmune Shock

Biomarker	Change
IL-6	↑↑
TNF-α	↑↑
HMGB1	↑↑
YKL-40	↑

Neurocardiac Shock

Biomarker	Change
SDNN	↓20%
LF/HF Ratio	>3

Neurovascular Shock

Biomarker	Change
MMP-9	↑↑
S100B	Mild ↑
Claudin-5	↑

Neurometabolic Shock

Biomarker	Change
Lactate	2–3 mmol/L
ATP Production	↓20%
cf-mtDNA	↑

Neuroendocrine Shock

Biomarker	Change
Cortisol	Sustained elevation
DHEA-S	↓

Early Symptoms

Brain fog
Sleep disturbance
Fatigue
Irritability
Reduced attention

Reversibility

Very High

V. PHASE D — EARLY TOXIC ENCEPHALOPATHY

SCF Classification

MNSS-II

Temporal Window

24–72 Hours

Dominant Shock State

Neuroimmune-Neurovascular Coupled Failure

Neuroglial Injury

Biomarker	Change
GFAP	↑25–100%
S100B	↑
YKL-40	↑↑

Neuroimmune Injury

Biomarker	Change
IL-6	↑↑↑
TNF-α	↑↑
IL-1β	↑

Neurocardiac Injury

Biomarker	Change
SDNN	<90 ms
RMSSD	↓↓

Neurovascular Injury

Biomarker	Change
MMP-9	↑↑↑
Albumin Quotient	↑

Clinical Features

Confusion
Delirium
Cognitive slowing
Memory impairment

Reversibility

High

VI. PHASE E — ESTABLISHED TOXIC ENCEPHALOPATHY

SCF Classification

MNSS-III

Temporal Window

Days to Weeks

Dominant Shock State

Neuroglial-Neuroaxonal Shock

Neuroaxonal Injury

Biomarker	Change
NfL	↑
UCH-L1	↑
NSE	↑
Total Tau	↑

Neuroglial Injury

Biomarker	Change
GFAP	↑↑
S100B	↑↑

Connectomic Injury

Biomarker	Change
qEEG Connectivity	↓
EEG Theta	↑
EEG Delta	↑

Neurometabolic Failure

Biomarker	Change
Lactate	>4 mmol/L
ATP Production	↓40%
cf-mtDNA	↑↑

Clinical Features

Severe cognitive dysfunction
Hallucinations
Executive impairment
Gait abnormalities

Reversibility

Moderate

VII. PHASE F — ACUTE MULTI-NEUROSYSTEMS SHOCK

SCF Classification

MNSS-IV

Temporal Window

Hours to Days

Dominant Shock State

Global Connectomic Collapse

Neuroimmune Shock

Peak:

IL-6
TNF-α
HMGB1

Neurocardiac Shock

Peak:

HRV suppression
Arrhythmogenic instability
Troponin elevation

Neurovascular Shock

Peak:

BBB disruption
MMP-9
S100B
VEGF

Neurometabolic Shock

Peak:

Lactate >5 mmol/L
ATP failure
cf-mtDNA peak

Neuroendocrine Shock

Peak:

Cortisol dysregulation
ACTH dysregulation
Melatonin suppression

Neuroinjury

Peak:

GFAP
NfL
UCH-L1
NSE

Connectomics

Severe:

DMN collapse
Salience collapse
Executive network collapse
Brainstem network instability

Clinical Features

Stupor
Coma
Seizures
Respiratory depression
Severe delirium

Reversibility

Limited

VIII. PHASE G — POST-TOXIC RECOVERY INITIATION

SCF Classification

MNSS-R1

Temporal Window

Days to Weeks

Dominant State

Shock Resolution

Biomarker Trends

Biomarker	Trend
IL-6	↓
TNF-α	↓
GFAP	↓
S100B	↓
Lactate	↓
Cortisol	Normalizing

Clinical Features

Improved attention
Improved wakefulness
Reduced delirium

Therapeutic Opportunity

Highest restorative response window

IX. PHASE H — CONNECTOMIC RECONSTRUCTION

SCF Classification

MNSS-R2

Temporal Window

Weeks to Months

Dominant State

Network Reintegration

Biomarker Trends

Biomarker	Recovery Signal
NfL	↓
GFAP	↓
qEEG Connectivity	↑
DTI FA	↑
HRV SDNN	↑
Cortisol Rhythm	Restored

Clinical Features

Cognitive recovery
Executive function improvement
Autonomic stabilization

X. PHASE I — POST-ENCEPHALOPATHY ADAPTIVE STATE

SCF Classification

MNSS-R3

Temporal Window

Months to Years

Residual Injury Biomarkers

Biomarker	Persistent Elevation Suggests
NfL	Chronic axonal injury
GFAP	Persistent astrocytosis
YKL-40	Chronic glial activation
HMGB1	Ongoing neuroimmune activation
SDNN Suppression	Chronic autonomic dysfunction
Cortisol Rhythm Loss	Chronic neuroendocrine maladaptation
qEEG Dysconnectivity	Residual connectomic injury

XI. MASTER SCF PRE/POST TOXIC ENCEPHALOPATHY BIOMARKER PANEL

Stage	Neuroimmune	Neurocardiac	Neurovascular	Neurometabolic	Neuroendocrine
Pre-Toxic	IL-6, TNF-α	HRV	MMP-9	Lactate/Pyruvate	Cortisol
Silent Priming	HMGB1, MCP-1	SDNN ↓	VEGF ↑	ATP ↓	ACTH ↑
Pre-Encephalopathy	YKL-40 ↑	LF/HF ↑	S100B ↑	cf-mtDNA ↑	DHEA-S ↓
Early Encephalopathy	GFAP ↑	HRV ↓↓	BBB markers ↑	Lactate ↑	Cortisol dysregulation
Established	NfL ↑	Troponin ↑	MMP-9 ↑↑	ATP failure	Circadian loss
Acute Shock	Peak cytokines	Severe HRV collapse	Peak BBB injury	Peak lactate	HPA collapse
Recovery	Cytokines ↓	HRV ↑	BBB repair	Lactate ↓	Rhythm normalization
Reconstruction	GFAP ↓	SDNN ↑	MMP-9 ↓	ATP recovery	Endocrine restoration

XII. SCF THERAPEUTIC TEMPORAL WINDOW MATRIX

Window	SCF State	Reversibility	Clinical Objective
Window 1	MNSS-IA	Very High	Prevent neuroimmune priming
Window 2	MNSS-IB	Very High	Prevent encephalopathy onset
Window 3	MNSS-II	High	Prevent neuroaxonal injury
Window 4	MNSS-III	Moderate	Stabilize connectomic collapse
Window 5	MNSS-IV	Limited	Preserve life and neurological function
Window 6	MNSS-R1	High	Accelerate recovery
Window 7	MNSS-R2	Moderate-High	Restore networks
Window 8	MNSS-R3	Variable	Prevent chronic dysfunction

MASTER REGISTRY INDEX

SCF-ECCA-TOX-TEMP-0003 — Toxic Encephalopathy Temporal Window Atlas
SCF-MNSS-0001 — Multi-Neurosystems Shock State Framework
SCF-ECCA-TOX-0001 — Toxic Encephalopathy Module
SCF-CONNECTOMIC-RECONSTRUCTION-0001 — Neuroimmune Connectomic Reconstruction Framework
SCF-BIOMARKER-ENDPOINTS-0001 — Biomarker Endpoint Validation Framework
SCF-PATH-PROT-0001 — SCF Pathophysiology Protocol
SCF-ACU-NEURO-ATLAS-0001 — SCF Neural Mapping Schema